amphetamine has been researched along with Nerve Degeneration in 63 studies
Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.
1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.
amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The dopamine-releasing and depleting substance amphetamine (AMPH) can make cortical neurons susceptible to damage, and the prevention of hyperthermia, seizures and stroke is thought to block these effects." | 7.71 | Parvalbumin neuron circuits and microglia in three dopamine-poor cortical regions remain sensitive to amphetamine exposure in the absence of hyperthermia, seizure and stroke. ( Bowyer, JF; Jakab, RL, 2002) |
| "The influence of embryonic mesencephalic, striatal and mesencephalic/striatal co-grafts on amphetamine- and apomorphine-induced rotation behaviour was assessed in a rat model of multiple system atrophy/striatonigral degeneration type using dopamine D1 ([3H]SCH23390) and D2 ([3H]spiperone) receptor and dopamine re-uptake ([3H]mazindol) autoradiography." | 7.70 | Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesenc ( Granata, R; Jenner, P; Laboyrie, P; Poewe, W; Puschban, Z; Quinn, NP; Scherfler, C; Wenning, GK, 2000) |
| "The dopamine-releasing and depleting substance amphetamine (AMPH) can make cortical neurons susceptible to damage, and the prevention of hyperthermia, seizures and stroke is thought to block these effects." | 3.71 | Parvalbumin neuron circuits and microglia in three dopamine-poor cortical regions remain sensitive to amphetamine exposure in the absence of hyperthermia, seizure and stroke. ( Bowyer, JF; Jakab, RL, 2002) |
| "The influence of embryonic mesencephalic, striatal and mesencephalic/striatal co-grafts on amphetamine- and apomorphine-induced rotation behaviour was assessed in a rat model of multiple system atrophy/striatonigral degeneration type using dopamine D1 ([3H]SCH23390) and D2 ([3H]spiperone) receptor and dopamine re-uptake ([3H]mazindol) autoradiography." | 3.70 | Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesenc ( Granata, R; Jenner, P; Laboyrie, P; Poewe, W; Puschban, Z; Quinn, NP; Scherfler, C; Wenning, GK, 2000) |
| " These results suggest that the chronic administration of clobenzorex may decrease motor function in a manner similar to amphetamine, via the neuroadaptive and non-neurotoxic changes caused to the striatum under this administration scheme." | 1.62 | The Chronic Oral Administration of Clobenzorex or Amphetamine Decreases Motor Behavior and Induces Glial Activation in the Striatum Without Dopaminergic Degeneration. ( Apóstol Del Rosal, GD; Limón, ID; Martínez, I; Patricio-Martínez, A, 2021) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| "5 mg/kg) were examined in the parietal cortex of rats pretreated for nine days with either saline, non-neurotoxic amphetamine, or neurotoxic AMPH dosing regimens." | 1.34 | A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes. ( Bowyer, JF; Delongchamp, RR; Freeman, WM; O'Callaghan, JP; Patel, KM; Pogge, AR; Vrana, KE, 2007) |
| "Depression is the most common psychiatric complication in Parkinson's disease (PD)." | 1.34 | Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. ( Juckel, G; Klein, J; Kupsch, A; Lee, T; Morgenstern, R; Mundt, A; Petrus, D; von Rumohr, A; Winter, C, 2007) |
| "Methamphetamine (METH) is a psychostimulant that induces excessive release of dopamine (DA) in the striatum." | 1.33 | Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors. ( Angulo, JA; Xu, W; Zhu, JP, 2005) |
| " In addition the home cage behaviour of mice administered with the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) using an acute dosing regimen was also investigated." | 1.33 | Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration. ( Billinton, A; Brown, M; Chapman, H; Quinn, LP; Stean, TO; Upton, N; Vidgeon-Hart, M; Virley, DJ, 2006) |
| " Another subgroup of Mnd mutants were treated with the metabolites of (-)-deprenyl, a mixture of (-)-amphetamine and (-)-methamphetamine, at a dosage equimolar to 1." | 1.29 | (-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants. ( Bhattacharya, N; Holland, D; Murray, B; Oh, C; Tatton, WG, 1994) |
| "Using the excitotoxic animal model of Huntington's disease, two experimental treatments were evaluated." | 1.28 | Neural grafts and pharmacological intervention in a model of Huntington's disease. ( Ford, LM; Giordano, M; Sanberg, PR; Shipley, MT, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (26.98) | 18.7374 |
| 1990's | 11 (17.46) | 18.2507 |
| 2000's | 25 (39.68) | 29.6817 |
| 2010's | 9 (14.29) | 24.3611 |
| 2020's | 1 (1.59) | 2.80 |
| Authors | Studies |
|---|---|
| Apóstol Del Rosal, GD | 1 |
| Limón, ID | 1 |
| Martínez, I | 1 |
| Patricio-Martínez, A | 1 |
| Leeboonngam, T | 1 |
| Pramong, R | 1 |
| Sae-Ung, K | 2 |
| Govitrapong, P | 2 |
| Phansuwan-Pujito, P | 2 |
| Faustini, G | 1 |
| Longhena, F | 1 |
| Varanita, T | 1 |
| Bubacco, L | 1 |
| Pizzi, M | 1 |
| Missale, C | 1 |
| Benfenati, F | 1 |
| Björklund, A | 6 |
| Spano, P | 1 |
| Bellucci, A | 1 |
| Xilouri, M | 1 |
| Brekk, OR | 1 |
| Landeck, N | 1 |
| Pitychoutis, PM | 1 |
| Papasilekas, T | 1 |
| Papadopoulou-Daifoti, Z | 1 |
| Kirik, D | 4 |
| Stefanis, L | 1 |
| Shin, E | 1 |
| Rogers, JT | 1 |
| Devoto, P | 1 |
| Carta, M | 1 |
| Schwerk, A | 1 |
| Altschüler, J | 1 |
| Roch, M | 1 |
| Gossen, M | 1 |
| Winter, C | 2 |
| Berg, J | 1 |
| Kurtz, A | 1 |
| Akyüz, L | 1 |
| Steiner, B | 1 |
| Hao, F | 1 |
| Yang, C | 1 |
| Chen, SS | 1 |
| Wang, YY | 1 |
| Zhou, W | 1 |
| Hao, Q | 1 |
| Lu, T | 1 |
| Hoffer, B | 2 |
| Zhao, LR | 1 |
| Duan, WM | 1 |
| Xu, QY | 1 |
| McCoy, MK | 2 |
| Ruhn, KA | 2 |
| Martinez, TN | 2 |
| McAlpine, FE | 1 |
| Blesch, A | 1 |
| Tansey, MG | 2 |
| Schmued, L | 2 |
| Bowyer, J | 1 |
| Cozart, M | 1 |
| Heard, D | 1 |
| Binienda, Z | 2 |
| Paule, M | 1 |
| Bowyer, JF | 6 |
| Thomas, M | 1 |
| Schmued, LC | 1 |
| Ali, SF | 1 |
| Marques, E | 1 |
| Vasconcelos, F | 1 |
| Rolo, MR | 1 |
| Pereira, FC | 1 |
| Silva, AP | 1 |
| Macedo, TR | 1 |
| Ribeiro, CF | 1 |
| Pothakos, K | 1 |
| Kurz, MJ | 1 |
| Lau, YS | 1 |
| Glavaski-Joksimovic, A | 1 |
| Virag, T | 1 |
| Chang, QA | 1 |
| West, NC | 1 |
| Mangatu, TA | 1 |
| McGrogan, MP | 1 |
| Dugich-Djordjevic, M | 1 |
| Bohn, MC | 1 |
| Grealish, S | 1 |
| Mattsson, B | 1 |
| Draxler, P | 1 |
| Falk, T | 1 |
| Yue, X | 1 |
| Zhang, S | 1 |
| McCourt, AD | 1 |
| Yee, BJ | 1 |
| Gonzalez, RT | 1 |
| Sherman, SJ | 1 |
| Uéda, K | 1 |
| Ellison, G | 2 |
| Jakab, RL | 2 |
| Muñoz, A | 1 |
| Lopez-Real, A | 1 |
| Labandeira-Garcia, JL | 1 |
| Guerra, MJ | 1 |
| Delongchamp, RR | 2 |
| Dong, Z | 1 |
| Wolfer, DP | 1 |
| Lipp, HP | 1 |
| Büeler, H | 1 |
| Yasuhara, T | 1 |
| Shingo, T | 1 |
| Muraoka, K | 1 |
| wen Ji, Y | 1 |
| Kameda, M | 1 |
| Takeuchi, A | 1 |
| Yano, A | 1 |
| Nishio, S | 1 |
| Matsui, T | 1 |
| Miyoshi, Y | 1 |
| Hamada, H | 1 |
| Date, I | 1 |
| Xu, W | 1 |
| Zhu, JP | 1 |
| Angulo, JA | 1 |
| Anderson, KK | 1 |
| Ballok, DA | 1 |
| Prasad, N | 1 |
| Szechtman, H | 1 |
| Sakic, B | 1 |
| Saravanan, KS | 1 |
| Sindhu, KM | 1 |
| Senthilkumar, KS | 1 |
| Mohanakumar, KP | 1 |
| Quinn, LP | 1 |
| Stean, TO | 1 |
| Chapman, H | 1 |
| Brown, M | 1 |
| Vidgeon-Hart, M | 1 |
| Upton, N | 1 |
| Billinton, A | 1 |
| Virley, DJ | 1 |
| Cunha-Oliveira, T | 1 |
| Rego, AC | 1 |
| Cardoso, SM | 1 |
| Borges, F | 1 |
| Swerdlow, RH | 1 |
| Macedo, T | 1 |
| de Oliveira, CR | 1 |
| Szymkowski, DE | 1 |
| Smith, CG | 1 |
| Botterman, BR | 1 |
| Tansey, KE | 1 |
| Pogge, AR | 1 |
| O'Callaghan, JP | 1 |
| Patel, KM | 1 |
| Vrana, KE | 1 |
| Freeman, WM | 1 |
| von Rumohr, A | 1 |
| Mundt, A | 1 |
| Petrus, D | 1 |
| Klein, J | 1 |
| Lee, T | 1 |
| Morgenstern, R | 2 |
| Kupsch, A | 1 |
| Juckel, G | 1 |
| Ricaurte, GA | 1 |
| Seiden, LS | 1 |
| Schuster, CR | 1 |
| Nozaki, M | 1 |
| Bell, JA | 1 |
| Martin, WR | 1 |
| Winkelmann, E | 1 |
| Oelssner, W | 1 |
| Brauer, K | 1 |
| Hedlich, A | 1 |
| Werner, L | 1 |
| Senitz, D | 1 |
| Nwanze, E | 1 |
| Jonsson, G | 3 |
| Linder, JC | 2 |
| Young, SJ | 1 |
| Groves, PM | 2 |
| Oestreicher, E | 1 |
| Sengstock, GJ | 1 |
| Riederer, P | 1 |
| Olanow, CW | 1 |
| Dunn, AJ | 1 |
| Arendash, GW | 1 |
| Oh, C | 1 |
| Murray, B | 1 |
| Bhattacharya, N | 1 |
| Holland, D | 1 |
| Tatton, WG | 1 |
| Bazzett, TJ | 1 |
| Becker, JB | 1 |
| Kaatz, KW | 1 |
| Albin, RL | 1 |
| Clausing, P | 2 |
| Davies, DL | 1 |
| Newport, GD | 1 |
| Scallet, AC | 1 |
| Slikker, W | 1 |
| Nakao, N | 1 |
| Brundin, P | 1 |
| Frame, LT | 1 |
| Nagamoto-Combs, K | 1 |
| Osterhout, CA | 1 |
| Sterling, CR | 1 |
| Tank, AW | 1 |
| Rosenblad, C | 3 |
| Devaux, B | 1 |
| Moffat, B | 1 |
| Phillips, HS | 1 |
| Puschban, Z | 1 |
| Scherfler, C | 1 |
| Granata, R | 1 |
| Laboyrie, P | 1 |
| Quinn, NP | 1 |
| Jenner, P | 1 |
| Poewe, W | 1 |
| Wenning, GK | 1 |
| Lacroix, L | 1 |
| Spinelli, S | 1 |
| White, W | 1 |
| Feldon, J | 1 |
| Georgievska, B | 1 |
| Crocker, SJ | 1 |
| Wigle, N | 1 |
| Liston, P | 1 |
| Thompson, CS | 1 |
| Lee, CJ | 1 |
| Xu, D | 1 |
| Roy, S | 1 |
| Nicholson, DW | 1 |
| Park, DS | 1 |
| MacKenzie, A | 1 |
| Korneluk, RG | 1 |
| Robertson, GS | 1 |
| Moore, AE | 1 |
| Cicchetti, F | 1 |
| Hennen, J | 1 |
| Isacson, O | 1 |
| Herman, ZS | 1 |
| Ungerstedt, U | 3 |
| Ljungberg, T | 2 |
| Siggins, G | 1 |
| Giordano, M | 1 |
| Ford, LM | 1 |
| Shipley, MT | 1 |
| Sanberg, PR | 1 |
| Hovda, DA | 1 |
| Sutton, RL | 1 |
| Feeney, DM | 1 |
| Ryan, LJ | 1 |
| Woodruff, GN | 1 |
| Elkhawad, AO | 1 |
| Crossman, AR | 1 |
| Andén, NE | 1 |
| Asher, IM | 1 |
| Aghajanian, GK | 1 |
| Fibiger, HC | 1 |
| Phillips, AG | 1 |
| Steg, G | 1 |
| Sachs, C | 2 |
| Malmfors, T | 1 |
| Thoa, NB | 1 |
| Eichelman, B | 1 |
| Ng, LK | 1 |
2 reviews available for amphetamine and Nerve Degeneration
| Article | Year |
|---|---|
Electron microscopic evidence for neurotoxicity in the basal ganglia.
Topics: Amphetamine; Animals; Basal Ganglia; Hydroxydopamines; Image Processing, Computer-Assisted; Microsco | 1995 |
5-hydroxytryptamine metabolism in the brain under the influence of psychotropic drugs.
Topics: Amphetamine; Amphetamines; Animals; Antidepressive Agents, Tricyclic; Brain; Fenclonine; Hallucinoge | 1975 |
61 other studies available for amphetamine and Nerve Degeneration
| Article | Year |
|---|---|
The Chronic Oral Administration of Clobenzorex or Amphetamine Decreases Motor Behavior and Induces Glial Activation in the Striatum Without Dopaminergic Degeneration.
Topics: Administration, Oral; Amphetamine; Amphetamines; Animals; Corpus Striatum; Dopamine Uptake Inhibitor | 2021 |
Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Dopaminergic Neurons; Hippocampus; Melatoni | 2018 |
Synapsin III deficiency hampers α-synuclein aggregation, striatal synaptic damage and nigral cell loss in an AAV-based mouse model of Parkinson's disease.
Topics: alpha-Synuclein; Amphetamine; Animals; Central Nervous System Stimulants; Dependovirus; Mice; Mice, | 2018 |
Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Apomorphine; Autophagy; Cells, Cultured | 2013 |
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic Agents; Adrenergic Neurons; Amphetamine; Animals; Antiparkinson Agents; Apomorphine; Benz | 2014 |
Adipose-derived human mesenchymal stem cells induce long-term neurogenic and anti-inflammatory effects and improve cognitive but not motor performance in a rat model of Parkinson's disease.
Topics: Adipose Tissue; Amphetamine; Animals; Anti-Inflammatory Agents; Cognition; Disease Models, Animal; D | 2015 |
Long-term protective effects of AAV9-mesencephalic astrocyte-derived neurotrophic factor gene transfer in parkinsonian rats.
Topics: Adenoviridae; Adrenergic Agents; Amphetamine; Animals; Cells, Cultured; Disease Models, Animal; Dopa | 2017 |
Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats.
Topics: Amphetamine; Animals; Behavior, Animal; Brain; Cell Nucleus; Cells, Cultured; Cytoplasm; Dependoviru | 2008 |
Introducing Black-Gold II, a highly soluble gold phosphate complex with several unique advantages for the histochemical localization of myelin.
Topics: Amphetamine; Animals; Fluoresceins; Kainic Acid; Myelin Sheath; Nerve Degeneration; Organic Chemical | 2008 |
Brain region-specific neurodegenerative profiles showing the relative importance of amphetamine dose, hyperthermia, seizures, and the blood-brain barrier.
Topics: Amphetamine; Animals; Blood-Brain Barrier; Central Nervous System Stimulants; Fever; Hippocampus; Hu | 2008 |
Influence of chronic exercise on the amphetamine-induced dopamine release and neurodegeneration in the striatum of the rat.
Topics: Amphetamine; Animals; Central Nervous System Stimulants; Corpus Striatum; Dopamine; Humans; Male; Mi | 2008 |
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.
Topics: Amphetamine; Animals; Bone Marrow Cells; Cell Communication; Cell Line; Corpus Striatum; Disease Mod | 2009 |
Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agen | 2010 |
Vascular endothelial growth factor-B is neuroprotective in an in vivo rat model of Parkinson's disease.
Topics: Amphetamine; Animals; Behavioral Symptoms; Cell Count; Central Nervous System Stimulants; Disease Mo | 2011 |
Melatonin reduces the expression of alpha-synuclein in the dopamine containing neuronal regions of amphetamine-treated postnatal rats.
Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Animals, Newborn; Brain; Dopamine; Mela | 2012 |
Neural degeneration following chronic stimulant abuse reveals a weak link in brain, fasciculus retroflexus, implying the loss of forebrain control circuitry.
Topics: Amphetamine; Animals; Brain; Central Nervous System Stimulants; Cocaine; Habenula; Haplorhini; Human | 2002 |
Parvalbumin neuron circuits and microglia in three dopamine-poor cortical regions remain sensitive to amphetamine exposure in the absence of hyperthermia, seizure and stroke.
Topics: Amphetamine; Animals; Astrocytes; Cerebral Cortex; Dopamine; Drug Residues; Fever; Glial Fibrillary | 2002 |
Interaction between the noradrenergic and serotonergic systems in locomotor hyperactivity and striatal expression of Fos induced by amphetamine in rats.
Topics: Adrenergic alpha-Antagonists; Amphetamine; Animals; Behavior, Animal; Central Nervous System Stimula | 2003 |
Glutamate N-methyl-D-aspartate and dopamine receptors have contrasting effects on the limbic versus the somatosensory cortex with respect to amphetamine-induced neurodegeneration.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Dopamine Agents; Excitatory Amino Acid Antagonists; Limbi | 2004 |
Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apoptosis; Behavior, Animal; Dep | 2005 |
The differences between high and low-dose administration of VEGF to dopaminergic neurons of in vitro and in vivo Parkinson's disease model.
Topics: Amphetamine; Animals; Cell Survival; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Respons | 2005 |
Induction of striatal pre- and postsynaptic damage by methamphetamine requires the dopamine receptors.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Apoptosis; Basal Ganglia Diseases; Corpus Stria | 2005 |
Impaired response to amphetamine and neuronal degeneration in the nucleus accumbens of autoimmune MRL-lpr mice.
Topics: Amphetamine; Analysis of Variance; Animals; Behavior, Animal; Disease Models, Animal; Dopamine Uptak | 2006 |
L-deprenyl protects against rotenone-induced, oxidative stress-mediated dopaminergic neurodegeneration in rats.
Topics: Amphetamine; Animals; Catalase; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Rel | 2006 |
Further validation of LABORAS using various dopaminergic manipulations in mice including MPTP-induced nigro-striatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Apomorphine; Automation; Behavio | 2006 |
Mitochondrial dysfunction and caspase activation in rat cortical neurons treated with cocaine or amphetamine.
Topics: Amphetamine; Amphetamine-Related Disorders; Animals; Apoptosis; Caspases; Cell Line, Tumor; Central | 2006 |
Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
Topics: Amphetamine; Animals; Cell Death; Cells, Cultured; Coculture Techniques; Disease Models, Animal; Dop | 2006 |
A threshold neurotoxic amphetamine exposure inhibits parietal cortex expression of synaptic plasticity-related genes.
Topics: Amphetamine; Animals; Body Temperature; Body Weight; Central Nervous System Stimulants; DNA, Complem | 2007 |
Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats.
Topics: Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antidepressive Agents; Behavior, Anim | 2007 |
Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine nerve fibers.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Male; Methampheta | 1984 |
Noradrenergic action of amphetamine following degeneration of descending monoaminergic fibers in the spinal cord.
Topics: Amphetamine; Animals; Biogenic Amines; Female; Hydroxydopamines; Methoxamine; Nerve Degeneration; Ne | 1980 |
[Degenerative changes in the occipital neocortex in chronically amphetamine treated rats].
Topics: Amphetamine; Animals; Axons; Dendrites; Male; Nerve Degeneration; Neurons; Occipital Lobe; Rats; Rat | 1983 |
Amphetamine neurotoxicity on dopamine nerve terminals in the caudate nucleus of mice.
Topics: Amphetamine; Animals; Caudate Nucleus; Dopamine; Fluorescence; Histocytochemistry; Male; Mice; Nerve | 1981 |
Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study.
Topics: Amphetamine; Animals; Behavior, Animal; Corpus Striatum; Histocytochemistry; Iron; Male; Medial Fore | 1994 |
(-)-Deprenyl alters the survival of adult murine facial motoneurons after axotomy: increases in vulnerable C57BL strain but decreases in motor neuron degeneration mutants.
Topics: Amphetamine; Animals; Axons; Cell Survival; Facial Nerve; Methamphetamine; Mice; Mice, Inbred A; Mic | 1994 |
Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration.
Topics: Amphetamine; Animals; Atrophy; Corpus Striatum; Dialysis; Dose-Response Relationship, Drug; Electron | 1993 |
Parenterally administered 3-nitropropionic acid and amphetamine can combine to produce damage to terminals and cell bodies in the striatum.
Topics: Amphetamine; Animals; Behavior, Animal; Biogenic Monoamines; Body Temperature; Central Nervous Syste | 1996 |
Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid.
Topics: Amphetamine; Animals; Apomorphine; Cell Survival; Cyclic N-Oxides; Dopamine Agonists; Dopamine and c | 1997 |
Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats.
Topics: Aging; Amphetamine; Animals; Blotting, Western; Dopamine; Dopamine Uptake Inhibitors; Glyceraldehyde | 1998 |
Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Dopamine; Female; Forelimb; Microinjections; Mot | 1998 |
Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle.
Topics: Amphetamine; Animals; Antibodies; Apomorphine; Atrophy; Body Weight; Cerebral Ventricles; Corpus Str | 1999 |
Autoradiographic study of striatal dopamine re-uptake sites and dopamine D1 and D2 receptors in a 6-hydroxydopamine and quinolinic acid double-lesion rat model of striatonigral degeneration (multiple system atrophy) and effects of embryonic ventral mesenc
Topics: Amphetamine; Animals; Apomorphine; Atrophy; Autoradiography; Behavior, Animal; Brain Tissue Transpla | 2000 |
The effects of ibotenic acid lesions of the medial and lateral prefrontal cortex on latent inhibition, prepulse inhibition and amphetamine-induced hyperlocomotion.
Topics: Amphetamine; Animals; Denervation; Disease Models, Animal; Dopamine; Hyperkinesis; Ibotenic Acid; Ma | 2000 |
Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Female; Glial Cell Line-Derived Neurotrophic Factor | 2001 |
NAIP protects the nigrostriatal dopamine pathway in an intrastriatal 6-OHDA rat model of Parkinson's disease.
Topics: Amphetamine; Amyloid beta-Protein Precursor; Animals; Antibodies; Caspase 3; Caspases; Cell Survival | 2001 |
Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat.
Topics: Amphetamine; Animals; Apomorphine; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Agonists; E | 2001 |
Dopaminergic supersensitivity in the striatum.
Topics: Amphetamine; Apomorphine; Caudate Nucleus; Corpus Striatum; Cyclic AMP; Dopamine; Hydroxydopamines; | 1975 |
Continuous amphetamine and cocaine have similar neurotoxic effects in lateral habenular nucleus and fasciculus retroflexus.
Topics: Amphetamine; Animals; Cocaine; Nerve Degeneration; Raphe Nuclei; Rats; Thalamic Nuclei | 1992 |
Neural grafts and pharmacological intervention in a model of Huntington's disease.
Topics: Acetylcholinesterase; Amphetamine; Animals; Brain Tissue Transplantation; Catalepsy; Cerebral Cortex | 1990 |
Amphetamine-induced recovery of visual cliff performance after bilateral visual cortex ablation in cats: measurements of depth perception thresholds.
Topics: Amphetamine; Animals; Cats; Depth Perception; Discrimination Learning; Dominance, Cerebral; Female; | 1989 |
Amphetamine changes neostriatal morphology.
Topics: Amphetamine; Animals; Corpus Striatum; Dopamine; Nerve Degeneration; Neuronal Plasticity | 1987 |
Further evidence for the stimulation of rat brain dopamine receptors by ergometrine.
Topics: Amphetamine; Animals; Brain Chemistry; Corpus Striatum; Dopamine; Ergonovine; Functional Laterality; | 1974 |
Effect of acute axotomy (spinal cord transection) on the turnover of 5-hydroxytryptamine.
Topics: Acetamides; Amphetamine; Animals; Catechols; Fenclonine; Hallucinogens; Hydroxyindoleacetic Acid; Ly | 1974 |
Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour.
Topics: Amphetamine; Animals; Apomorphine; Brain; Butyrophenones; Dopamine; Electrocoagulation; Haloperidol; | 1971 |
6-Hydroxydopamine lesions of olfactory tubercles and caudate nuclei: effect on amphetamine-induced stereotyped behavior in rats.
Topics: Amphetamine; Animals; Apomorphine; Behavior; Behavior, Animal; Brain Chemistry; Brain Mapping; Cauda | 1974 |
Role of dopamine and norepinephrine in the chemistry of reward.
Topics: Amphetamine; Animals; Brain; Dopamine; Dose-Response Relationship, Drug; Electrodes, Implanted; Halo | 1974 |
Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.
Topics: Amphetamine; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Drinking Behavior; Elect | 1974 |
Pharmacological modifications of the 6-hydroxy-dopa induced degeneration of central noradrenaline neurons.
Topics: Amphetamine; Animals; Brain; Caudate Nucleus; Cerebral Cortex; Chromatography; Dihydroxyphenylalanin | 1973 |
Effects of drugs on the 6-hydroxydopamine induced degeneration of adrenergic nerves.
Topics: Amphetamine; Animals; Bretylium Compounds; Dopamine; Drug Interactions; Heart Atria; Histocytochemis | 1972 |
Shock-induced aggression: effects of 6-hydroxydopamine and other pharmacological agents.
Topics: Aggression; Amphetamine; Animals; Apomorphine; Brain; Catecholamines; Desipramine; Dihydroxyphenylal | 1972 |